Saturday 17 October 2026 Export RXRX’s income statement to Excel — free account

Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024. In the quarter to June 2026, revenue fell 60.1%, EPS grew 39.0%, free cash flow fell 32.0% and total debt fell 66.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

3.47 0.69 −16.59%

Follow RXRX

Alert me

Market cap: $2.2B
P/E: 0.0×
Fwd P/E: −3.8×
Dividend yield: —
F-score: 3/9
Altman Z: 0.37
Beneish M: −1.72
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

	Jun '26	Mar '26	Dec '25	Sep '25	Older periods
P/E ratio Full definition →	0.00	0.00	0.00	0.00	+8 more quarters Free account
P/S ratio Full definition →	35.62	24.47	24.51	49.93
P/FCF ratio Full definition →	0.00	0.00	0.00	0.00
P/Operating CF Full definition →	(18.44)	(20.04)	(39.72)	(18.59)
P/B ratio Full definition →	2.14	1.59	1.62	2.08
Price to Tangible BV Full definition →	4.14	2.85	2.78	3.88
EV/Sales Full definition →	25.66	14.64	14.62	35.03
EV/EBITDA Full definition →	0.00	0.00	0.00	0.00
EV/Operating CF Full definition →	(4.02)	(3.03)	(2.94)	(3.47)
EV/FCF Full definition →	(3.97)	(2.96)	(2.87)	(3.40)
Quick Ratio Full definition →	4.72	5.19	5.23	4.42
Current Ratio Full definition →	5.03	5.47	5.50	4.60
Net Debt/EBITDA Full definition →	4.68	6.00	8.31	4.31
Debt/Assets Full definition →	0.39%	0.54%	0.65%	0.85%
Debt/Equity Full definition →	0.01	0.01	0.01	0.01
Asset Turnover Full definition →	0.04	0.05	0.05	0.04
Operating CF/Net income Full definition →	0.81	0.69	0.43	0.72
Capex/Depreciation Full definition →	(0.11)	(0.02)	(0.06)	(0.01)
Research and Development Expense of Revenue Full definition →	1,168.37%	1,358.10%	269.96%	2,339.36%
Selling, General and Administrative Expense of Revenue Full definition →	541.50%	534.47%	94.71%	804.41%
Intangible Assets out of Total Assets Full definition →	0.37	0.34	0.32	0.35
Share Based Compensation of Revenue Full definition →	254.21%	343.25%	66.87%	487.79%
Graham Net Nets Full definition →	0.16	0.24	0.26	0.17
Graham Number Full definition →	0.00	0.00	0.00	0.00
Earnings Yield Full definition →	(28.34%)	(39.09%)	(36.19%)	(36.89%)
Free Cash Flow Yield Full definition →	(18.13%)	(20.19%)	(20.79%)	(20.64%)
Revenue per Share Full definition →	0.01	0.01	0.08	0.01
Operating CF per Share Full definition →	(0.20)	(0.15)	(0.10)	(0.26)
Capex per Share Full definition →	0.00	0.00	0.00	0.00
Free Cash Flow per Share Full definition →	(0.20)	(0.15)	(0.11)	(0.26)
Cash per Share Full definition →	1.03	1.25	1.67	1.48
Shareholders Equity per Share Full definition →	1.72	1.94	2.53	2.34
Interest Debt per Share Full definition →	0.00	0.00	0.00	0.00
Book value per Share Full definition →	1.72	1.94	2.53	2.34
Free Cash Flow Full definition →	(107.91)	(81.44)	(47.32)	(117.60)
Working Capital Full definition →	483.58	579.86	665.14	559.00
Capital Expenditures Full definition →	(1.96)	(0.34)	(1.24)	(0.24)
Net Current Asset Value Full definition →	305.80	394.80	469.58	361.53
EV/EBIT Full definition →	0.00	0.00	0.00	0.00
Capex to Sales Full definition →	0.26	0.05	0.04	0.05
Price to Operating Income Full definition →	0.00	0.00	0.00	0.00
Other line items
Average Receivables Full definition →	18.00	29.85	36.91	12.08
Average Payables Full definition →	15.99	22.72	19.87	8.10
Average Assets Full definition →	1,257.51	1,322.38	1,461.36	1,063.01
Average Common Equity Full definition →	917.07	979.36	1,082.82	785.75

Show all line items

Columns are period end dates

Stockrow Weekly